Simulation and comparison of progression-free survival among patients with non-squamous non-small-cell lung cancer receiving sequential therapy

References

• Sant M, Aareleid T, Berrino F, et al. EUROCARE-3: survival of cancer patients diagnosed 1990–1994 – results and commentary. Ann Oncol 2003;14:v61-v118
   PubMed Web of Science ®Google Scholar
• Ferlay J, Shin HR, Bray F, et al. GLOBOCAN 2008 v1.2, Cancer incidence and mortality worldwide. IARC CancerBase No 10. 2008
   Google Scholar
• Goldstraw P, Crowley J, Chansky K, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2007;2:706-14
   PubMed Web of Science ®Google Scholar
• American Cancer Society. Cancer facts & figures 2009. American Cancer Society; 2009
   Google Scholar
• Groome PA, Bolejack V, Crowley JJ, et al. The IASLC Lung Cancer Staging Project: validation of the proposals for revision of the T, N, and M descriptors and consequent stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol 2007;2:694-705
   PubMed Web of Science ®Google Scholar
• Peters S, Adjei AA, Gridelli C, et al. Metastatic Non-Small Cell Lung Cancer: ESMO Clinical Practice Guidelines. Ann Oncol 2012;23(Suppl):vii56-64
   PubMedGoogle Scholar
• National Comprehensive Cancer network (NCCN). Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer V.1.2014
   Google Scholar
• Group, N.-s.C.L.C.C. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995;311:899-909
   PubMedGoogle Scholar
• Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346(2):92-8
   PubMed Web of Science ®Google Scholar
• Rossi A, Maione P, Colantuoni G, et al. Recent developments of targeted therapies in the treatment of non-small cell lung cancer. Curr Drug Discov Technol 2009;6:91-102
   PubMedGoogle Scholar
• Pallis AG, Serfass L, Dziadziusko R, et al. Targeted therapies in the treatment of advanced/metastatic NSCLC. Eur J Cancer 2009;45:2473-87
   PubMed Web of Science ®Google Scholar
• Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26(21):3543-51
   PubMed Web of Science ®Google Scholar
• Crino L, Dansin E, Garrido P, et al. Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study. Lancet Oncol 2010;11(8):733-40
   PubMed Web of Science ®Google Scholar
• Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22(9):1589-97
   PubMed Web of Science ®Google Scholar
• Patel JD, Socinski MA, Garon EB, et al. A Randomized, Open-Label, Phase III, Superiority Study of Pemetrexed(Pem) + Carboplatin(Cb) + Bevacizumab(Bev) Followed by Maintenance Pem + Bev versus Paclitaxel (Pac)+Cb+Bev Followed by Maintenance Bev in Patients with Stage IIIB or IV Non-Squamous Non-Small Cell Lung Cancer (NS-NSCLC). In: Oral Presentation at Chicago Multidisciplinary Symposium in Thoracic Oncology; Chicago, USA; 2012
   Google Scholar
• Paz-Ares L, de Marinis F, Dediu M, et al. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. Lancet Oncol 2012;13(3):247-55
   PubMed Web of Science ®Google Scholar
• Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009;27(8):1227-34
   PubMed Web of Science ®Google Scholar
• Reck M, von Pawel J, Zatloukal P, et al. Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann Oncol 2010;21(9):1804-9
   PubMed Web of Science ®Google Scholar
• Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355(24):2542-50
   PubMed Web of Science ®Google Scholar
• Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353(2):123-32
   PubMed Web of Science ®Google Scholar
• Zinner R, Ross HJ, Weaver R, et al. PRONOUNCE: Randomized, open-label, phase 3 study of pemetrexed (Pem) + carboplatin (Cb) followed by maintenance pemetrexed vs. paclitaxel (Pac) + carboplatin + bevacizumab (Bev) followed by maintenance bevacizumab in patients with advanced non-squamous non-small-cell lung cancer (NS-NSCLC). In: Oral Presentation at ASCO Meeting; Chicago, USA; 2013
   Google Scholar
• Summary of product characteristics - Avastin. Available from: www.avastin.net/smpc.html [Last accessed 31 January 2014]
   Google Scholar
• Summary of product characteristics - pemetrexed. Available from: www.medicines.org.uk/emc/medicine/15513 [Last accessed 31 January 2014]
   Google Scholar
• Summary of product characteristics - erlotinib. Available from: www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000618/WC500033994.pdf [Last accessed 31 January 2014]
   Google Scholar
• Summary of product characteristics - docetaxel. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000073/WC500035264.pdf [Last accessed 31 January 2014]
   Google Scholar
• Hoyle MW, Henley W. Improved curve fits to summary survival data: application to economic evaluation of health technologies. BMC Med Res Methodol 2011;11:139
   PubMed Web of Science ®Google Scholar
• Tierney JF, Stewart LA, Ghersi D, et al. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007;8:16
   PubMed Web of Science ®Google Scholar
• Patel JD, Socinski MA, Garon EB, et al. PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. J Clin Oncol 2013;31(34):4349-57
   PubMed Web of Science ®Google Scholar